Evidence map›Paper›PMID 29950703›Full record

ArticleScientific reports2018

Novel haptens and monoclonal antibodies with subnanomolar affinity for a classical analytical target, ochratoxin A.

Daniel López-Puertollano, Josep V Mercader, Consuelo Agulló, Antonio Abad-Somovilla, Antonio Abad-Fuentes

Abstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniel López-PuertollanoDepartment of Organic Chemistry, University of Valencia, Doctor Moliner 50, 46100, Burjassot, Valencia, Spain.
Josep V MercaderInstitute of Agrochemistry and Food Technology (IATA), Spanish National Research Council (CSIC), Agustí Escardino 7, 46980, Paterna, Valencia, Spain.
Consuelo AgullóDepartment of Organic Chemistry, University of Valencia, Doctor Moliner 50, 46100, Burjassot, Valencia, Spain.
Antonio Abad-SomovillaDepartment of Organic Chemistry, University of Valencia, Doctor Moliner 50, 46100, Burjassot, Valencia, Spain.
Antonio Abad-FuentesInstitute of Agrochemistry and Food Technology (IATA), Spanish National Research Council (CSIC), Agustí Escardino 7, 46980, Paterna, Valencia, Spain. aabad@iata.csic.es.ORCID 0000-0001-5672-1438

Funding

Ministerio de Economía y Competitividad (Ministry of Economy and Competitiveness) AGL2012-39965-C02Ministerio de Economía y Competitividad (Ministry of Economy and Competitiveness) AGL2015-64488-C2Ministerio de Educación, Cultura y Deporte (Ministry of Education, Culture and Sports, Spain) FPU14/05266
6 · The paper itself

Abstract

Ochratoxin A is a potent toxic fungal metabolite whose undesirable presence in food commodities constitutes a problem of public health, so it is strictly regulated and controlled. For the first time, two derivatives of ochratoxin A (OTAb and OTAd) functionalized through positions other than the native carboxyl group of the mycotoxin, have been synthesized in order to better mimic, during the immunization process, the steric and conformational properties of the target analyte. Additionally, two conventional haptens making use of that native carboxyl group for protein coupling (OTAe and OTAf) were also prepared as controls for the purpose of comparison. The immunological performance in rabbits of protein conjugates based on OTAb and OTAd overcome that of conjugates employing OTAe and OTAf as haptens. After immunization of mice with OTAb and OTAd conjugates, a collection of high-affinity monoclonal antibodies to ochratoxin A was generated. In particular, one of those antibodies, the so-called OTAb#311, is very likely the best antibody produced so far in terms of selectivity and affinity to ochratoxin A.

Indexed as

Antibodies, MonoclonalEnzyme-Linked Immunosorbent AssayHaptensMolecular StructureOchratoxinsAntibodies, MonoclonalHaptensochratoxin AOchratoxins

Identifiers

PMID29950703
PMCPMC6021394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.